18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

Brain

Volumn 139, Issue 9, 2016, Pages 2372-2379

  Smith, Ruben ^a,b   Puschmann, Andreas ^a,b   Schöll, Michael ^c,d   Ohlsson, Tomas ^b   Van Swieten, John ^e   Honer, Michael ^f   Englund, Elisabet ^g   Hansson, Oskar ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g LUND UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; frontotemporal dementia; MAPT R406W mutation; positron emission tomography; tau

Indexed keywords

FLORTAUCIPIR F 18; FLUTEMETAMOL F 18; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; MAPT PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BRAIN ATROPHY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE MUTATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; PET SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TAUOPATHY; TEMPORAL LOBE; ATROPHY; DEMENTIA; DIAGNOSTIC IMAGING; GENETICS; HETEROZYGOTE; MEMORY DISORDER; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES;

AGED; ATROPHY; CARBOLINES; DEMENTIA; FEMALE; HETEROZYGOTE; HIPPOCAMPUS; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TEMPORAL LOBE;

EID: 84994896458     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww163     Document Type: Article

References (25)

1. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457-68.
2. Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging 2016; 43: 1139-50.
3. Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. Invited review: frontotemporal dementia caused by microtubuleassociated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 2015; 41: 24-46.
4. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med 2016; 57: 208-14.
5. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998; 282: 1914-17.
6. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5?-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5.
7. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 2016; 12: 15-27.
8. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol 2016; 79: 110-9.
9. Lindquist SG, Holm IE, Schwartz M, Law I, Stokholm J, Batbayli M, et al. Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. Eur J Neurol 2008; 15: 377-85.
10. Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787-800.
11. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009; 50: 1251-9.
12. Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol 2015; 77: 338-42.
13. Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 2016; 139: 1151-67.
14. Ostojic J, Elfgren C, Passant U, Nilsson K, Gustafson L, Lannfelt L, et al. The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dement Geriatr Cogn Disord 2004; 17: 298-301.
15. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-Amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-9.
16. Passant U, Ostojic J, Froelich Fabre S, Gustafson L, Lannfelt L, Larsson EM, et al. Familial presenile dementia with bitemporal atrophy. Dement Geriatr Cogn Disord 2004; 17: 287-92.
17. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med 2015; 21: 394-402.
18. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-94.
19. Reed LA, Grabowski TJ, Schmidt ML, Morris JC, Goate A, Solodkin A, et al. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol 1997; 42: 564-72.
20. Ronn LC, Ralets I, Hartz BP, Bech M, Berezin A, Berezin V, et al. A simple procedure for quantification of neurite outgrowth based on stereological principles. J Neurosci Methods 2000; 100: 25-32.
21. Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, et al. Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement 2016, doi: 10.1016/j.jalz.2016.01.003.
22. Scholl M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron 2016; 89: 971-82.
23. Smith R, Wibom M, Olsson T, Hagerstrom D, Jogi J, Rabinovici GD, et al. Posterior accumulation of tau and concordant hypometabolism in an early-onset Alzheimer's disease patient with presenilin-1 mutation. J Alzheimers Dis 2016; 51: 339-43.
24. Villemagne VL, Okamura N. Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Curr Opin Neurobiol 2015; 36: 43-51.
25. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013; 9: 666-76.